MNKD - MannKind Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.1200
-0.0250 (-2.18%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.1450
Open1.1500
Bid0.0000 x 39400
Ask1.1600 x 1000
Day's Range1.0800 - 1.1900
52 Week Range0.9400 - 3.0400
Volume3,163,815
Avg. Volume2,132,282
Market Cap210.317M
Beta (3Y Monthly)2.19
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    MannKind Corporation Reports 2019 Second Quarter Financial Results and Recent Business Highlights

    2Q 2019 Total Revenues of $15.0 million; +285% vs. 2Q 2018  º  2Q 2019 Afrezza Net Revenue was $6.1 million; +62% vs. 2Q 2018  º  2Q 2019 Collaboration and Services Revenue was.

  • GlobeNewswire

    MannKind and One Drop Sign Collaboration Agreement to Integrate Bluetooth-Connected Inhaler with Dose Detection into the One Drop Platform

    WESTLAKE VILLAGE, Calif., Aug. 05, 2019 -- MannKind Corporation (NASDAQ: MNKD) and One Drop today announced that they have signed a collaborative agreement that is intended to.

  • GlobeNewswire

    MannKind Corporation to Hold 2019 Second Quarter Financial Results Conference Call on August 7, 2019

    MannKind Corporation (MNKD) will release its 2019 second quarter and year-to-date financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August 7, 2019. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.  MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.

  • GlobeNewswire

    Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients Opens Enrollment for Cohort 3

    MannKind Corporation (MNKD) announced today that the Afrezza® safety and pharmacokinetics study in pediatric patients is now enrolling children 4-7 years of age (Cohort 3) and nearing completion for Cohort 2 (8-12 years of age). An interim review of data from individuals participating in the second cohort shows that the single‑dose pharmacokinetic profile of insulin levels for this age group is consistent with the pattern seen in adults. In addition, dosing over one month demonstrated a safety profile that was also consistent with that observed in adults.  As a result of these findings, MannKind and the study investigators are proceeding with enrollment of the third cohort of subjects.

  • GlobeNewswire

    MannKind Repays Maturing Debt Obligation; Buys Back Certain Warrants

    WESTLAKE VILLAGE, Calif., July 18, 2019 -- MannKind Corporation (NASDAQ: MNKD) today announced the repayment of outstanding debt by an aggregate amount of approximately $4.0.

  • GlobeNewswire

    MannKind Partners with GoodRx to Help Raise Awareness on Reducing Out of Pocket Insulin Cost for Patients

    WESTLAKE VILLAGE, Calif., July 15, 2019 (GLOBE NEWSWIRE) --  MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that it has partnered with GoodRx to help raise awareness on ways patients can save money on their mealtime insulin.

  • GlobeNewswire

    MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules

    MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced that it has completed construction of a new high-potency manufacturing suite in its Danbury Connecticut facility.  This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships. The new suite will house bulk powder formulation and fill/pack operations for high-potency powders and adds to MannKind's extensive commercial manufacturing capability, which includes inhalation devices, large-scale compounding, particle formation, tangential flow filtration, cryogranulation, and high capacity (300 kg/day) lyophilization.

  • GlobeNewswire

    MannKind to Present at the JMP Securities Life Sciences Conference

    WESTLAKE VILLAGE, Calif., June 12, 2019 -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for.

  • GlobeNewswire

    MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions

    MannKind Corporation (MNKD) announced that new data from three different studies of Afrezza® (insulin human) Inhalation Powder were released at the American Diabetes Association’s 79th Scientific Sessions, being held June 7-11, in San Francisco, California. MannKind will present a poster with initial information from its ongoing study of Safety and Pharmacokinetics of Technosphere Insulin (Afrezza) in Pediatric Patients ¹ on Monday, June 10.  This study is the first step in preparation for a phase 3 safety and efficacy study.

  • GlobeNewswire

    Afrezza® (insulin human) Inhalation Powder Approved in Brazil

    Afrezza® is the only orally inhaled ultra rapid-acting mealtime insulin approved by ANVISA in Brazil. WESTLAKE VILLAGE, Calif. and BELO HORIZONTE, Brazil, June 03, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) and BIOMM SA (BIOM3.SA) today announced that Afrezza® (insulin human) Inhalation Powder, an ultra rapid-acting mealtime insulin to improve glycemic control in adult patients with diabetes mellitus, has been registered by the Brazilian Health Regulatory Agency (ANVISA).

  • GlobeNewswire

    MannKind Announces Afrezza® Distribution Agreement in Australia

    MannKind Corporation (MNKD) today announced that it has entered into an exclusive marketing and distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific Ltd. for the commercialization of Afrezza® (insulin human) Inhalation Powder in Australia. "We are excited to partner with AMSL Diabetes to accelerate patients’ access to Afrezza in Australia," said Michael Castagna, Chief Executive Officer of MannKind Corporation.

  • GlobeNewswire

    MannKind Corporation Reports 2019 First Quarter Financial Results

    1Q 2019 Total Revenues of $17.4 million 1Q 2019 Afrezza Net Revenue was $5.1 million; +49% vs. 1Q 2018 1Q 2019 Collaborations and Services Revenue was $12.4 million 1Q 2019 net.

  • GlobeNewswire

    MannKind Corporation to Hold 2019 First Quarter Financial Results Conference Call on May 7, 2019

    WESTLAKE VILLAGE, Calif., April 30, 2019 -- MannKind Corporation (Nasdaq:MNKD) will release its 2019 first quarter financial results on Tuesday, May 7, 2019 and its management.

  • GlobeNewswire

    MannKind Presents Scientific Data at 28th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE 2019)

    WESTLAKE VILLAGE, Calif., April 25, 2019 -- MannKind Corporation (Nasdaq:MNKD) today announced additional data supporting the distinct clinical profile of Afrezza will be.

  • GlobeNewswire

    MannKind to Present at the H.C. Wainwright Global Life Sciences Conference

    If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com ) to register for the conference.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company. The presentation will be webcast live.  To access the webcast, please visit www.hcwevents.com.  Interested parties can also access a link to the live webcast of the presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com.  The webcast replay will remain available for 14 days following the live presentation.

  • GlobeNewswire

    MannKind Receives $12.5 Million Milestone Payment from United Therapeutics

    MannKind Corporation (MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil.  Treprostinil Technosphere (“TreT”) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension.  Pursuant to the agreement, MannKind is eligible to earn additional payments up to $37.5 million upon the achievement of other defined development milestones.  MannKind will also be entitled to receive low double-digit royalties on net sales of TreT.

  • GlobeNewswire

    MannKind to Sponsor Andretti Autosport Type 1 Diabetes Driver, Conor Daly

    MannKind Corporation (MNKD) announced today it is sponsoring Conor Daly as he makes his debut with the Andretti Autosport team at the 103rd Running of the Indianapolis 500 on May 26, 2019. MannKind is an associate sponsor of Andretti Autosport for this race and will partner with Daly on his No. 25 U.S. Air Force Honda.

  • ACCESSWIRE

    These Four Healthcare Stocks Are Making Moves on Wednesday

    CORAL GABLES, FL / ACCESSWIRE / March 13, 2019 / The healthcare stock market has managed to attract significant attention in the initial months of 2019 as a result of healthcare companies demonstrating to investors and consumers their commitment to the future of the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NVAX), Advaxis Inc (ADXS), and MannKind Corporation (MNKD) are 4 healthcare companies raising the bar on Wednesday. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care.

  • GlobeNewswire

    MannKind Corporation Fourth Quarter and Year-End 2018 Earnings Call

    Conference Call to Begin Today at 9:00 AM ET 4Q 2018 Total Revenues were $16.0 million; 254% growth vs. 4Q 2017 4Q 2018 Afrezza Net Revenue was $5.7 million; 28% growth vs. 4Q.

  • ACCESSWIRE

    MannKind Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 26, 2019 / MannKind Corporation (NASDAQ: MNKD ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 at 9:00 ...

  • GlobeNewswire

    MannKind Presents New Scientific Data at 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)

    WESTLAKE VILLAGE, Calif., Feb. 20, 2019 -- MannKind Corporation (Nasdaq:MNKD) today announced additional positive Afrezza clinical data to be presented in an oral presentation.

  • GlobeNewswire

    MannKind Corporation Participating at Upcoming Conferences

    WESTLAKE VILLAGE, Calif., Feb. 20, 2019 -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for.

  • GlobeNewswire

    MannKind Corporation to Hold 2018 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2019

    WESTLAKE VILLAGE, Calif., Feb. 19, 2019 -- MannKind Corporation (Nasdaq:MNKD) will release its 2018 fourth quarter and full year financial results on Tuesday, February 26, 2019.

  • GlobeNewswire

    Market Trends Toward New Normal in MannKind, IDEX, Belden, Bright Horizons Family Solutions, Masonite International, and Veritiv — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 05, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE

    Biotech Stocks on the Move

    HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotech has been one of the hottest sectors this month. Investors are intrigued by the increase in M&A. Now's a great time to start researching some oversold ...